{
  "context": {
    "rules": [
      "Rule1: If drug X requires a black box warning, then drug X requires a warning label.",
      "Rule2: Either drug X receives fast track approval, or if the absence of mild side effects does not imply drug X is safe for use, then drug X requires a black box warning.",
      "Rule3: Provided that phase 1 for drug X is complete, drug X is safe for use.",
      "Rule4: Whenever phase 2 for drug X is complete, drug X is safe for use.",
      "Rule5: If animal testing for drug X is complete, then phase 1 for drug X is complete.",
      "Rule6: In the event that preliminary human trials for drug X are complete, phase 2 for drug X is complete.",
      "Rule7: Should a safety profile for drug X be established, then either animal testing for drug X is complete or preliminary human trials for drug X are complete.",
      "Rule8: Assuming efficacy of drug X is demonstrated, then either animal testing for drug X is complete or preliminary human trials for drug X are complete.",
      "Rule9: Drug X is withdrawn from the market, or a safety profile for drug X is established, or efficacy of drug X is demonstrated.",
      "Rule10: Either drug X is rejected, or drug X is pending review.",
      "Rule11: Drug X is voluntarily recalled, or it is not the case that drug X is withdrawn from the market.",
      "Rule12: Provided that drug X has a regulatory violation, a fine is imposed on drug X.",
      "Rule13: Whenever drug X has a regulatory violation, criminal charges are filed for drug X.",
      "Rule14: Drug X has a regulatory violation, or if drug X is rejected, then it is not the case that drug X is approved.",
      "Rule15: Should the license for drug X be suspended, then it is not the case that a fine is imposed on drug X.",
      "Rule16: If criminal charges are filed for drug X, then the license for drug X is suspended.",
      "Rule17: Assuming drug X is patent protected, then it is not the case that drug X is approved.",
      "Rule18: Provided that drug X has exclusive marketing rights, then it is not the case that a generic version of drug X is available.",
      "Rule19: If the patent for drug X has expired, then if it is not the case that drug X is patent protected, drug X has exclusive marketing rights.",
      "Rule20: In the event that the patent for drug X is challenged, then if it is not the case that drug X is patent protected, drug X has exclusive marketing rights.",
      "Rule21: Should drug X be pending review, then it is not the case that drug X is approved.",
      "Rule22: If a generic application for drug X is submitted, then the patent for drug X has expired.",
      "Rule23: Provided that a biosimilar application for drug X is submitted, then the patent for drug X is challenged.",
      "Rule24: Whenever the price of drug X is reduced, competitive market entry occurs for drug X.",
      "Rule25: The price of drug X is reduced, or drug X experiences market share loss.",
      "Rule26: Drug X has orphan drug status, or it is not the case that drug X requires a clinical trial.",
      "Rule27: If drug X has a rare disease indication, then it is not the case that drug X has orphan drug status.",
      "Rule28: Either drug X has a rare disease indication, or drug X addresses an unmet medical need.",
      "Rule29: In case drug X addresses an unmet medical need, then it is not the case that drug X has orphan drug status.",
      "Rule30: Provided that drug X requires monitoring, then drug X is safe for use.",
      "Rule31: Should drug X be under post-market surveillance, then if drug X has mild side effects, drug X requires monitoring.",
      "Rule32: Drug X is under post-market surveillance, or drug X has a risk management program.",
      "Rule33: Assuming adverse event reporting is conducted for drug X, then if the absence of mild side effects does not imply drug X is safe for use, drug X requires a warning label.",
      "Rule34: Adverse event reporting is conducted for drug X, or a patient registry exists for drug X.",
      "Rule35: Either an audit is scheduled for drug X, or an inspection is required for drug X.",
      "Rule36: Whenever an inspection is required for drug X, then if it is not the case that a patient registry exists for drug X implies that if the absence of mild side effects does not imply drug X is safe for use, then drug X requires a warning label, then drug X has a data integrity issue.",
      "Rule37: Should drug X be compliance certified, then if an audit is scheduled for drug X, then if it is not the case that a patient registry exists for drug X implies that if the absence of mild side effects does not imply drug X is safe for use, then drug X requires a warning label, then drug X has a data integrity issue.",
      "Rule38: If drug X requires special handling, then drug X has restricted distribution.",
      "Rule39: Provided that drug X is a controlled substance, then if the absence of mild side effects does not imply drug X is safe for use, drug X requires special handling.",
      "Rule40: If a prescription is required for drug X, then a specialist referral is required for drug X.",
      "Rule41: In case a prescription is required for drug X, then it is not the case that physician authorization is needed for drug X.",
      "Rule42: Should a specialist referral be required for drug X, then physician authorization is needed for drug X.",
      "Rule43: If drug X has a quality control issue, then a batch recall is issued for drug X.",
      "Rule44: Either drug X has a quality control issue, or drug X has a contamination risk.",
      "Rule45: Provided that drug X has a contamination risk, then either drug X has a manufacturing defect or it is not the case that drug X is withdrawn from the market.",
      "Rule46: In the event that a batch recall is issued for drug X, then either drug X has a manufacturing defect or it is not the case that drug X is withdrawn from the market.",
      "Rule47: Either production of drug X is halted, or drug X has a raw material shortage.",
      "Rule48: Should drug X have a raw material shortage, then either a safety profile for drug X is established or efficacy of drug X is demonstrated.",
      "Rule49: If a manufacturing audit is conducted for drug X, then if production of drug X is halted, drug X has a supply shortage.",
      "Rule50: A manufacturing audit is conducted for drug X, or process validation is performed for drug X.",
      "Rule51: Provided that process validation is performed for drug X, then if production of drug X is halted, drug X has a supply shortage.",
      "Rule52: In case the shelf life of drug X is reduced, then either drug X has a stability issue or it is not the case that drug X is withdrawn from the market.",
      "Rule53: If drug X has storage requirements, then the shelf life of drug X is reduced.",
      "Rule54: Whenever drug X is temperature sensitive, then drug X has storage requirements.",
      "Rule55: Provided that drug X has severe side effects, then drug X has side effects.",
      "Rule56: Drug X has severe side effects, or drug X has mild side effects.",
      "Rule57: If it is not the case that if drug X is rejected, then it is not the case that drug X is approved, then drug X requires a clinical trial.",
      "Rule58: Should it not be the case that if drug X experiences market share loss, then either a generic application for drug X is submitted or a biosimilar application for drug X is submitted, then profitability of drug X declines.",
      "Rule59: If it is not the case that if drug X experiences market share loss, then either a generic application for drug X is submitted or a biosimilar application for drug X is submitted, then it is not the case that profitability of drug X declines.",
      "Rule60: Provided that it is not the case that if drug X requires a clinical trial, then the clinical trial for drug X is completed, then the clinical trial for drug X has failed.",
      "Rule61: In the event that it is not the case that if drug X requires a clinical trial, then the clinical trial for drug X is completed, then it is not the case that the clinical trial for drug X has failed.",
      "Rule62: Assuming it is not the case that if drug X has a risk management program, then if drug X has mild side effects, drug X requires monitoring, then there are safety concerns for drug X.",
      "Rule63: Should it not be the case that if a patient registry exists for drug X, then if the absence of mild side effects does not imply drug X is safe for use, then drug X requires a warning label, then it is not the case that drug X has a data integrity issue.",
      "Rule64: If the absence of mild side effects does not imply drug X is safe for use, then it is not the case that drug X requires a warning label.",
      "Rule65: Assuming the absence of mild side effects does not imply drug X is safe for use, then it is not the case that drug X has restricted distribution.",
      "Rule66: Should it not be the case that drug X is patent protected, then a generic version of drug X is available.",
      "Rule67: In the event that it is not the case that drug X is a controlled substance, then a prescription is required for drug X.",
      "Rule68: If it is not the case that drug X is safe for use, then drug X is approved."
    ],
    "facts": [
      "Fact1: Drug X is compliance certified.",
      "Fact2: Drug X is temperature sensitive.",
      "Fact3: It is not the case that drug X receives fast track approval.",
      "Fact4: It is not the case that drug X is voluntarily recalled.",
      "Fact5: It is not the case that competitive market entry occurs for drug X.",
      "Fact6: It is not the case that there are safety concerns for drug X.",
      "Fact7: It is not the case that the clinical trial for drug X is completed.",
      "Fact8: It is not the case that drug X has a manufacturing defect.",
      "Fact9: It is not the case that drug X has a supply shortage.",
      "Fact10: It is not the case that drug X has a stability issue.",
      "Fact11: It is not the case that drug X has side effects."
    ]
  },
  "question": "Drug X is safe for use."
}